Fatty Liver Disease

A common, usually silent buildup of fat in the liver. An ultrasound often finds it; the question that matters is whether scarring has started.

Last updated October 2026 · New Dawn Health editorial team

How common
An estimated 25–30% of adults (AASLD)
Symptoms
Usually none until it is advanced
First-line test
Abdominal ultrasound, plus blood tests
Key modifiable factor
Weight, diet, and blood sugar

What is fatty liver disease?

Fatty liver disease is a buildup of excess fat inside liver cells. This page covers the kind linked to weight, blood sugar and cholesterol, now called metabolic dysfunction-associated steatotic liver disease (MASLD). Its older name was non-alcoholic fatty liver disease (NAFLD).

Alcohol causes fatty liver too, and the two causes can overlap. US liver specialists (AASLD) estimate that 25–30% of adults have the metabolic kind.

A sonographer presses an ultrasound probe to the upper abdomen of a patient lying on the exam table.
Fatty liver is often first seen on an abdominal ultrasound done for another reason.

Why scarring is what matters

In many people the fat stays mild. In some, it drives inflammation, called MASH. Over years, that inflammation can scar the liver (fibrosis), and heavy scarring becomes cirrhosis. Scarring, not the amount of fat, is what predicts serious liver problems.

Fat without much scarring
  • Often improves with weight, diet and blood-sugar control
  • Still worth a scarring check, because fat alone does not show it
When scarring builds
  • Needs closer monitoring, usually by a liver specialist
  • Elastography, an ultrasound-based stiffness test, measures how far it has gone

Why it usually has no symptoms

Fatty liver usually causes no symptoms, so it is far more often found by a scan than by how you feel. Some people notice vague tiredness or a dull ache under the right ribs.

  • Yellowing of the skin or eyes, or a swollen belly or legs: see a doctor promptly. These can be signs of advanced disease.
  • Fat found on a scan, no symptoms: ask for a FIB-4 score from your blood results.

Who is at risk

The strongest links are metabolic:

  • Overweight or obesity, especially weight around the middle
  • Type 2 diabetes or prediabetes
  • High triglycerides, low HDL cholesterol, or high blood pressure
  • A family history of cirrhosis, which AASLD treats as high risk

Lean people can develop it too, so a normal weight does not rule it out.

How it is found and treated

The tests used for fatty liver, and what each can and cannot show.
Test What it shows Its limit
Abdominal ultrasound Liver fat, as a brighter texture Can miss milder fat; cannot measure scarring
Blood tests Liver enzymes and metabolic markers; the inputs for FIB-4 Enzymes can be normal even when fat is present
FIB-4 score Whether advanced scarring is unlikely A score that is not low needs a second test
Elastography Liver stiffness, a measure of scarring A separate test, usually after FIB-4
MRI fat measurement The amount of liver fat, precisely Needs a specific MRI technique (PDFF) that a general survey scan may not include

Lifestyle change is the first treatment at every stage. In the US, two medicines are approved for MASH with moderate-to-advanced scarring: resmetirom (2024, only without cirrhosis) and semaglutide (2025). Whether either is available or suitable in Taiwan is a question for your doctor.

New Dawn Health offers abdominal ultrasound and blood tests in Taipei. Whether elastography or an MRI fat measurement is available with a booking is confirmed when you book.

Sources & further reading

  1. [1] AASLD practice guidance on the clinical assessment and management of NAFLD (Rinella 2023) — prevalence 25–30%; FIB-4 risk assessment; ultrasound insensitive for mild fat; MRI-PDFF — Hepatology / PMC
  2. [2] A multisociety Delphi consensus statement on new fatty liver disease nomenclature (Rinella 2023) — MASLD and MASH — Hepatology / PubMed
  3. [3] FDA approves first treatment for patients with liver scarring due to fatty liver disease — Rezdiffra (resmetirom), March 2024 — US Food and Drug Administration
  4. [4] FDA approves treatment for serious liver disease known as MASH — Wegovy (semaglutide), August 2025 — US Food and Drug Administration
  5. [5] Diagnostic accuracy of ultrasonography for fatty liver: meta-analysis (Hernaez 2011) — 85% sensitivity for moderate-severe fat — Hepatology / PubMed
  6. [6] NAFLD & NASH (fatty liver disease) — NIH / NIDDK

Fatty Liver Disease — Frequently Asked Questions

Is fatty liver disease serious?

For many people it stays mild. In some, the fat drives inflammation (MASH) that can slowly scar the liver. That is why a fatty-liver finding should come with a check of scarring risk, starting with the FIB-4 blood-test score.

Can fatty liver be reversed?

Often, especially early. Weight loss and better diet, activity and blood-sugar control are the first treatment. In the US, two medicines are approved for MASH with moderate-to-advanced scarring: resmetirom (2024, only without cirrhosis) and semaglutide (2025). Availability in Taiwan is a question for your doctor.

How is fatty liver diagnosed?

Usually on an abdominal ultrasound, which can miss milder fat. Liver enzymes can be normal even when fat is present. Measuring fat precisely needs a specific MRI technique. Scarring is checked with FIB-4, and with elastography if FIB-4 is not low.

Do I need symptoms to have fatty liver?

No. It is usually silent and often found on a scan done for another reason. Yellowing of the skin or eyes, or a swollen belly or legs, can be signs of advanced liver disease and need a doctor promptly.

Screen smart. Travel once. Know where you stand.

Compare screening packages, see exactly what each one includes, or talk to a coordinator about fitting Fatty Liver Disease screening into your visit to Taiwan.